Humana Inc. (NYSE: HUM) saw its shares decline 1.79% on Friday, closing at $385.54, as investors digested the company's plan to exit certain Medicare Advantage plans in 2027, a move that will affect roughly 600,000 members. The Louisville, Kentucky-based insurer, which currently serves about 7.2 million Medicare Advantage members, expects the exits to result in a net membership reduction of approximately 360,000, after accounting for expected recapture of about 40% of those affected.
The decision is part of a deliberate strategy to improve profitability, with management prioritizing a sustainable individual Medicare Advantage margin of at least 3% by 2028. Chief Financial Officer Celeste Mellet emphasized that plans consuming capital without adequate returns will now face a higher hurdle. The affected plans are those with weaker capital returns, and the company is willing to sacrifice scale for financial health.
The 600,000 members slated for discontinuation represent roughly 8% of Humana's total Medicare Advantage membership. Of that number, the company projects it will retain about 240,000 members through alternative offerings, leaving a modeled net reduction of 360,000. This trade-off is central to the company's margin recovery plan, which has been challenged by elevated medical costs and other headwinds.
Financial Performance and Guidance
Humana's second-quarter adjusted earnings came in at $7.61 per share, up from $6.27 in the same period last year. However, the company maintained its adjusted 2026 guidance of at least $9.00 per share, while cutting its GAAP guidance to at least $6.52 from $8.36. The Insurance segment benefit ratio for the second quarter was 91.2%, with full-year guidance set at 92.75%, plus or minus 25 basis points.
The company's stock valuation stands near $46.3 billion, reflecting the market's cautious view of the membership reduction and the uncertain path to margin recovery. Investors are closely watching whether Humana can achieve its recapture targets and whether the margin improvement will materialize as planned.
Federal Rate Support and Industry Context
Federal rates provide some support for the company's strategy. The Centers for Medicare & Medicaid Services (CMS) projects that average Medicare Advantage payments will rise by 2.48% in 2027, or more than $13 billion. After accounting for estimated risk-score trends, the increase becomes 4.98%. However, these headline increases do not guarantee uniform gains across all contracts, as star ratings, local benchmarks, member risk, and benefit design all influence plan economics.
Humana's 2026 adjusted guidance already includes a headwind from star ratings, which can affect quality bonuses and, ultimately, profitability. The company's decision to exit underperforming plans is seen as a way to mitigate these pressures and focus resources on higher-return segments.
Member Impact and Timeline
Members in discontinued plans will receive non-renewal information before the annual election period, which runs from October 15 through December 7. Coverage selections become effective on January 1, 2027. This timeline gives affected members time to explore alternatives, either through Humana or other insurers.
The next major test for Humana will be retention. If the company can achieve a recapture rate above 40%, it would protect its scale while removing weaker plans. Conversely, a lower rate would deepen the membership decline and increase acquisition costs. Analysts are also watching for potential risks, including elevated utilization, star rating changes that could reduce quality bonuses, and richer benefit designs that could dilute margin gains.
Humana's stock has been volatile as investors weigh the long-term benefits of a leaner, more profitable Medicare Advantage portfolio against the short-term loss of membership. The company's ability to execute its margin recovery plan will be critical in the coming quarters.
